Norditropin Daily denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Denied Norditropin (Daily Growth Hormone) as Experimental

An experimental or investigational denial for Norditropin (somatropin daily injection) is unusual for FDA-approved indications but does occur when the specific diagnosis or indication listed on the prior-authorization request falls outside UHC's covered-indication list for growth hormone therapy, or when the clinical documentation does not adequately establish that the patient meets the criteria for a covered indication. UHC may also apply an experimental designation to certain growth hormone uses in adults, to specific diagnostic subtypes of growth hormone deficiency, or to indications that require confirmatory testing UHC considers insufficiently documented.

Because Norditropin is FDA-approved for several specific indications, an experimental denial should be challenged by demonstrating that the patient's diagnosis falls squarely within an FDA-approved indication and is supported by current endocrinology guideline standards.

## Federal Appeal Framework

• ACA §2719 external review: for fully insured non-grandfathered plans, independent external review is available after exhausting internal appeals. Confirm the filing deadline on your denial letter.
• ERISA §503 full-and-fair review: governs self-funded employer plans after internal exhaustion.
• Expedited review: request this if delay will cause serious deterioration in the patient's condition — particularly relevant for pediatric patients with active growth failure.

## Appeal Process and Timeline

1. Obtain UHC's growth hormone coverage policy and the specific experimental/investigational criterion cited in the denial. 2. Review the FDA-approved prescribing information for Norditropin to confirm which indications are approved and what clinical criteria apply. 3. File a Level 1 internal appeal within the deadline on your denial notice, directly addressing the specific indication and the documentation that supports it. 4. Escalate through internal levels and then to external review if denied.

## Documentation to Gather

• Diagnostic confirmation: complete endocrine workup documentation, including the diagnostic tests used to establish the underlying condition, with dates and results. Do not include specific numeric values in the appeal narrative — instead, state that results were consistent with the diagnostic criteria in the applicable endocrinology guideline. However, include the actual lab reports as attachments for the clinical reviewer.
• FDA label alignment: the prescriber's letter should explicitly identify the FDA-approved indication under which Norditropin is being prescribed and confirm the patient meets the clinical criteria described in the prescribing information.
• Prescriber letter: from the treating endocrinologist, explaining why this is not experimental — citing the FDA approval status of the indication and the current guideline standard of care (reference the applicable Endocrine Society or Pediatric Endocrine Society guideline by organization name).
• Relevant professional society guidance: the current Endocrine Society clinical practice guideline for the applicable condition, confirming that daily somatropin therapy is the recognized standard of care for this diagnosis.
• UHC policy response: a point-by-point rebuttal of each experimental/investigational criterion using the above documentation.

## Criteria-Mapping Structure

Build a table with each criterion from UHC's experimental/investigational policy in the left column and the corresponding documentation in the right column. For the indication criterion, map it to: (1) the FDA-approved indication text from the Norditropin prescribing label, (2) the chart diagnosis, and (3) the professional society guideline endorsement. For any confirmatory-testing criterion, attach the actual test reports and map them to the policy's requirements. This three-column approach — FDA label, chart, guideline — is the strongest structure for rebutting an experimental denial on an approved drug.